Hologic, Inc.
HOLX
Rank in Stocks
#1326
Hologic, Inc. is a medical technology company focused on designing, producing,... Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Share Price
$76.01
Last synced: 2026-04-07
Market Cap
$16.97B
Change (1 day)
0.00%
Change (1 year)
5.76%
Country
US
Trade Hologic, Inc. (HOLX)
Category
Healthcare
Revenue for Hologic, Inc. (HOLX)
Revenue in Dec 2025 TTM: $4.13B
According to Hologic, Inc. latest financial reports the company's current revenue (TTM) is $4.13B. In 2024 the company made a revenue of $4.03B a decrease compared to the revenue in the year 2023 that was $4.03B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Hologic, Inc. from 2000 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $4.13B | 0.63% |
| 2025 | $4.10B | 1.74% |
| 2024 | $4.03B | 0.00% |
| 2023 | $4.03B | -17.12% |
| 2022 | $4.86B | -13.66% |
| 2021 | $5.63B | 49.14% |
| 2020 | $3.78B | 12.15% |
| 2019 | $3.37B | 4.64% |
| 2018 | $3.22B | 5.20% |
| 2017 | $3.06B | 7.98% |
| 2016 | $2.83B | 4.72% |
| 2015 | $2.71B | 6.89% |
| 2014 | $2.53B | 1.54% |
| 2013 | $2.49B | 24.45% |
| 2012 | $2.00B | 11.92% |
| 2011 | $1.79B | 6.54% |
| 2010 | $1.68B | 2.59% |
| 2009 | $1.64B | -2.23% |
| 2008 | $1.67B | 126.78% |
| 2007 | $738.37M | 59.59% |
| 2006 | $462.68M | 60.83% |
| 2005 | $287.68M | 25.79% |
| 2004 | $228.71M | 12.09% |
| 2003 | $204.04M | 7.28% |
| 2002 | $190.19M | 6.56% |
| 2001 | $178.49M | 90.40% |
| 2000 | $93.75M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $11.03B | 167.41% |
US
|
|
| $34.74B | 741.81% |
FR
|
|
| - | - |
JP
|
|
| $20.84B | 405.02% |
US
|
|
| - | - |
CH
|
